Idiopathic Pulmonary Fibrosis (IPF) & GERD Trial Objective The purpose of this study is to measure and accurately identify the presence and severity of gastroesphageal reflux disease (GERD), commonly called acid reflux, in idiopathic pulmonary fibrosis (IPF) patients using the Supraglottic Index (SGI). The study also will determine if stomach reflux or abnormal swallowing are associated with the progression of IPF. Enrollment New enrollment for this trial is temporarily paused Who Can Participate Individuals ages 40-95 who have been diagnosed with IPF may be eligible to participate. Age: 40-95 Gender: Any Gender Estimated Time Commitment 5 visits over a 6-month period, visits are every 3 months × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Maria Saucedo 303.398.1790 Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Boehringer Ingelheim Principal Investigators Matthew Koslow, MD + × Matthew Koslow, MD Assistant Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Request More Information Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for this trial.